Rivaroxaban approval imminent for Afib

An FDA advisory panel voted 9-2 in favor of approving rivaroxaban for stroke prevention treatment in patients with Afib. It will be the 3rd oral anticoagulant (behind warfarin and dabigatran) approved for Afib stroke prevention (story)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment